Differences between post-authorization adverse drug reactions of biopharmaceuticals and small molecules

BioDrugs

Volumn 27, Issue 2, 2013, Pages 167-174

  Ebbers, Hans C ^a   Al Temimi, Esraa ^a   Moors, Ellen H M ^a   Mantel Teeuwisse, Aukje K ^a   Schellekens, Huub ^a,b   Leufkens, Hubert G M ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; IMMUNOMODULATING AGENT; PANITUMUMAB; RITUXIMAB; TRASTUZUMAB;

ARTICLE; AUTHORITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPEAN UNION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOGENICITY; IMMUNOPATHOLOGY; INFECTION; INFESTATION; KIDNEY DISEASE; OFF LABEL DRUG USE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SKIN DISEASE; UROGENITAL TRACT DISEASE; VASCULAR DISEASE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AGENTS; IMMUNOLOGIC FACTORS; PRODUCT SURVEILLANCE, POSTMARKETING; SMALL MOLECULE LIBRARIES;

EID: 84877054931     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0012-y     Document Type: Article

References (26)

1. Clark JB. Mechanisms of adverse drug reactions to biologics. In: Uetrecht J, editor. Adverse drug reactions. Berlin: Springer; 2010. p. 453-74.
2. Baumann A. Early development of therapeutic biologics: pharmacokinetics. Curr Drug Metab. 2006;7(7):15-21.
3. Giezen TJ, Mantel-Teeuwisse AK, Leufkens HG. Pharmacovigilance of biopharmaceuticals: challenges remain. Drug Saf. 2009;32(10):811-7.
4. Giezen TJ, Mantel-Teeuwisse AK, Meyboom RH, Straus SM, Leufkens HG, Egberts TC. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Drug Saf. 2010;33(10):865-78.
5. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300(16):1887-96.
6. Mol PG, Straus SM, Piening S, de Vries JT, de Graeff PA, Haaijer-Ruskamp FM. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. Drug Saf. 2010;33(6):463-74.
7. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215-20.
8. Motola D, De Ponti F, Poluzzi E, Martini N, Rossi P, Silvani MC, et al. An update on the first decade of the European centralized procedure: how many innovative drugs? Br J Clin Pharmacol. 2006;62(5):610-6.
9. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964-75.
10. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl. 2):1-70.
11. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294-300.
12. Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol. 2010;28(1):88-92.
13. Vial T, Descotes J. Immunosuppressive drugs and cancer. Toxicology. 2003;185(3):229-40.
14. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2011; 10 May 2011 (online). http://www.whocc.no/atc-ddd-index/. Accessed 18 Jun 2011.
15. Trusheim MR, Aitken ML, Berndt AR. Characterizing markets for biopharmaceutical innovations: do biologics differ from small molecules? Forum Health Econ Pol. 2010;13(1):1-45.
16. European Medicines Agency. EPARs for authorised medicinal products for human use [online]. http://www.ema.europa.eu/htms/human/epar/a.htm. Accessed 12 Jul 2011.
17. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737-44.
18. Lameire N, Kruse V, Rottey S. Nephrotoxicity of anticancer drugs: an underestimated problem? Acta Clin Belg. 2011;66(5):337-45.
19. Callreus T. Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning. Drug Saf. 2006;29(7):557-66.
20. Aronson JK. Adverse drug reactions: history, terminology, classification, causality, frequency, preventability. Stephens' Detection and evaluation of adverse drug reactions, pp. 1-119. Wiley Ltd, New York (2011).
21. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28(10):851-70.
22. Ferner RE, Aronson JK. EIDOS: a mechanistic classification of adverse drug effects. Drug Saf. 2010;33(1):15-23.
23. Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61(8):912-20.
24. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol. 2007;25(5):555-61.
25. Zink A, Askling J, Dixon WG, Klareskog L, Silman AJ, Symmons DP. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis. 2009;68(8):1240-6.
26. Frau S, Font Pous M, Luppino MR, Conforti A. Risk management plans: are they a tool for improving drug safety? Eur J Clin Pharmacol. 2010;66(8):785-90.